HS-10529 / Jiangsu Hansoh Pharma - LARVOL DELTA

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=520 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Monotherapy • New P1 trial • Solid Tumor

HANSOH PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA FOR HS-10529 in advanced solid tumors (Hansoh Pharma Press Release) - "Hansoh Pharma...announces that, HS-10529 tablets, a small molecule category i innovative drug targeting KRAS G12D self-developed by the group, has obtained the clinical trial approval issued by the national medical products administration (nmpa) of china, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations."

New trial • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer